Dupixent Asthma denied as non-formulary by Aetna?

Aetna's specific coverage criteria for dupixent asthma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Dupixent for Asthma as Non-Formulary — and How to Pursue a Formulary Exception

Aetna non-formulary denials for dupilumab (Dupixent) in asthma mean the drug is either not on your specific plan's formulary tier or requires a formulary exception before coverage is available. This is a coverage structure decision, not a safety or efficacy judgment — and it is appealable through both a formulary exception process and the standard internal/external appeal pathway.

### Why This Denial Is Appealable

Federal law requires health plans to have a formulary exception process for cases where a non-formulary drug is medically necessary because a formulary alternative is clinically inappropriate for the patient. Under ACA §2719 and ERISA §503, you are also entitled to a full-and-fair internal appeal and, if that fails, independent external review. For a drug with FDA approval for your specific condition, a non-formulary denial is often overturned when documentation shows that formulary alternatives are contraindicated, have failed, or are not clinically appropriate for your phenotype.

### Your Appeal Timeline

• Formulary exception request: Can often be filed simultaneously with or before an internal appeal; ask your prescriber to submit one with supporting documentation.
• Internal appeal: File within the deadline on your denial notice (commonly 180 days). Decisions within 30–60 days; expedited within 72 hours.
• External review: After internal denial, approximately four months to request independent external review.

### Documentation to Gather

1. Diagnosis confirmation — pulmonary function tests, specialist notes, and chart documentation confirming asthma diagnosis and severity. 2. Formulary alternative history — for each formulary biologic or alternative Aetna lists for your condition, document whether you have tried it and why it failed or is clinically inappropriate (adverse effects, inadequate response, contraindication per your physician). 3. Phenotype documentation — records supporting the inflammatory profile that aligns with the FDA-approved indication for dupilumab and distinguishes it from alternatives. 4. Clinical severity documentation — exacerbation rates, oral corticosteroid use, hospitalizations, and validated symptom scores. 5. Prescriber medical-necessity letter — your physician should explain why dupilumab specifically — and not a formulary alternative — is medically necessary for your case, citing the FDA-approved indication.

### Criteria-Mapping Structure

Obtain Aetna's formulary exception criteria and its clinical policy for dupilumab. Map each requirement to your record:

| Exception Criterion | Your Chart Evidence | |---|---| | Formulary alternative tried and failed | [Drug name, date, documented outcome] | | Formulary alternative clinically inappropriate | [Prescriber explanation, supporting chart note] | | Dupilumab matches FDA-approved indication | [Diagnosis, phenotype documentation] |

Review the current FDA-approved prescribing information for dupilumab to confirm the indication language, and attach it as an exhibit to your exception request and appeal.